[HTML][HTML] A 20-week program of resistance or concurrent exercise improves symptoms of schizophrenia: results of a blind, randomized controlled trial

B Andrade e Silva, RC Cassilhas, C Attux… - Revista Brasileira de …, 2015 - SciELO Brasil
Objective: To evaluate the effects of 20 weeks of resistance and concurrent training on
psychotic and depressive symptoms, quality of life outcomes, and serum IGF-1, IGFBP-3 …

[PDF][PDF] A 20-week program of resistance or concurrent exercise improves symptoms of schizophrenia: results of a blind, randomized controlled trial

BA e Silva, RC Cassilhas, C Attux, Q Cordeiro… - researchgate.net
Objective: To evaluate the effects of 20 weeks of resistance and concurrent training on
psychotic and depressive symptoms, quality of life outcomes, and serum IGF-1, IGFBP-3 …

[HTML][HTML] A 20-week program of resistance or concurrent exercise improves symptoms of schizophrenia: results of a blind, randomized controlled trial

RC Cassilhas, C Attux, Q Cordeiro, AL Gadelha… - Brazilian Journal of …, 2015 - bjp.org.br
OBJECTIVE: To evaluate the effects of 20 weeks of resistance and concurrent training on
psychotic and depressive symptoms, quality of life outcomes, and serum IGF-1, IGFBP-3 …

[HTML][HTML] A 20-week program of resistance or concurrent exercise improves symptoms of schizophrenia: results of a blind, randomized controlled trial

RC Cassilhas, C Attux, Q Cordeiro… - Brazilian Journal of …, 2015 - rbppsychiatry.org.br
OBJECTIVE: To evaluate the effects of 20 weeks of resistance and concurrent training on
psychotic and depressive symptoms, quality of life outcomes, and serum IGF-1, IGFBP-3 …

[HTML][HTML] A 20-week program of resistance or concurrent exercise improves symptoms of schizophrenia: results of a blind, randomized controlled trial

B Andrade e Silva, RC Cassilhas, C Attux… - Brazilian Journal of …, 2015 - SciELO Brasil
Objective: To evaluate the effects of 20 weeks of resistance and concurrent training on
psychotic and depressive symptoms, quality of life outcomes, and serum IGF-1, IGFBP-3 …

A 20-week program of resistance or concurrent exercise improves symptoms of schizophrenia: results of a blind, randomized controlled trial

B Andrade e Silva, RC Cassilhas, C Attux… - Revista Brasileira de …, 2015 - bv.fapesp.br
Objective: To evaluate the effects of 20 weeks of resistance and concurrent training on
psychotic and depressive symptoms, quality of life outcomes, and serum IGF-1, IGFBP-3 …

[HTML][HTML] A 20-week program of resistance or concurrent exercise improves symptoms of schizophrenia: results of a blind, randomized controlled trial

RC Cassilhas, C Attux, Q Cordeiro… - Brazilian Journal of …, 2015 - rbppsiquiatria.org.br
OBJECTIVE: To evaluate the effects of 20 weeks of resistance and concurrent training on
psychotic and depressive symptoms, quality of life outcomes, and serum IGF-1, IGFBP-3 …

[PDF][PDF] A 20-week program of resistance or concurrent exercise improves symptoms of schizophrenia: results of a blind, randomized controlled trial

BA e Silva, RC Cassilhas, C Attux, Q Cordeiro… - Revista Brasileira de …, 2015 - Citeseer
Objective: To evaluate the effects of 20 weeks of resistance and concurrent training on
psychotic and depressive symptoms, quality of life outcomes, and serum IGF-1, IGFBP-3 …

[PDF][PDF] A 20-week program of resistance or concurrent exercise improves symptoms of schizophrenia: results of a blind, randomized controlled trial

BA e Silva, RC Cassilhas, C Attux… - Revista Brasileira …, 2015 - pdfs.semanticscholar.org
Objective: To evaluate the effects of 20 weeks of resistance and concurrent training on
psychotic and depressive symptoms, quality of life outcomes, and serum IGF-1, IGFBP-3 …

A 20-week program of resistance or concurrent exercise improves symptoms of schizophrenia: results of a blind, randomized controlled trial

B Andrade e Silva, RC Cassilhas, C Attux, Q Cordeiro… - sidalc.net
Objective: To evaluate the effects of 20 weeks of resistance and concurrent training on
psychotic and depressive symptoms, quality of life outcomes, and serum IGF-1, IGFBP-3 …